TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03990506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-on PiXL
Description: Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epi-Off PiXL
Description: Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
Study: NCT03243175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: Apixaban 5mg x 2 during 24 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left atrial appendage closure
Description: left atrial appendage closure
Study: NCT03141541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based pain management intervention
Description: The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
Study: NCT02102399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Warm-up
Description: Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
Study: NCT03652675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
Description: This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
Study: NCT00745797

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
Study: NCT01524081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole, Cefuroxime
Description: administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole, Cefuroxime
Description: administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin (+ clavulanic acid) and Fluconazole
Description: Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. - 2x amoxicillin in 100ml saline~2. - Fluconazole in 500ml saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution
Study: NCT04115982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: One vial every 15 days during 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One vial every 15 days during 2 months
Study: NCT03753399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
Study: NCT00474461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: Intracoronary injection of cardiac stem cells
Study: NCT01085032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine
Description: Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nicotine patch
Description: Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used.
Study: NCT01084681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment of intracranial aneurysms
Description: Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment of intracranial aneurysm with coils
Description: Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
Study: NCT02858921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study: NCT04832763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review of medical charts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo physical function testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT02441556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular treatment
Description: The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard medical therapy
Description: If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
Study: NCT04594824

Intervention type: OTHER
Intervention: No Intervention
Description: no intervention

Intervention type: OTHER
Intervention: No Intervention
Description: no intervention
Study: NCT00651703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT004-MelQbG10 + Imiquimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT004-MelQbG10 intra nodal injection
Study: NCT03354715

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Rapid prototyping Denture base
Description: The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Heat Cured Conventional Complete Denture
Description: it is the main treatment for most of completely edentoulous Cases
Study: NCT03624920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THN102 Dosage A
Description: THN102 Dosages A: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102 Dosage B
Description: THN102 Dosage B : 200mg/2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102 Dosage C
Description: THN102 Dosage C: 200mg/18mg
Study: NCT02344082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
Study: NCT04563715

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV counseling and testing
Description: Receive HIV testing risk assessment and advice about risk reduction and future testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing
Description: Receive HIV testing risk assessment and advice about risk reduction and future testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network intervention
Description: Key individuals are trained to provide advice about regular testing and risk reduction.
Study: NCT01733810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of Acid Suppressing Medications
Description: Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
Study: NCT01838473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 1g, single dose. One pouch administered over 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 1g, single dose. One pouch administered over 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
Study: NCT02706483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Study: NCT05995691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: SC injection
Study: NCT01838473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
Study: NCT01382537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterX 5000
Description: A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
Study: NCT04834804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 12 weeks of exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 12 weeks of exercise training
Study: NCT02799849

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep and metabolism assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep and metabolism assessment
Study: NCT01382537

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: InterX 5000
Description: Placebo treatment
Study: NCT00430066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 400 mg/die for 6 months
Study: NCT01567150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Dressing
Description: Topical wound dressing
Study: NCT01997866

Intervention type: OTHER
Group type: OTHER
Intervention: STOP-BANG Scoring Model
Description: Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
Study: NCT04391504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study: NCT01997866

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnogram Sleep Study
Description: Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
Study: NCT01680432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic fresh cheese
Description: Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Regular Cheese
Study: NCT03271359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
Study: NCT01845480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness coaching
Description: Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness coaching
Description: Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
Study: NCT00973063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine sterile gloving
Description: routinely new sterile gloving just before sampling
Study: NCT02910011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanodox 1% (doxycycline monohydrate hydrogel)
Description: Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
Study: NCT03168334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Tazarotene 0.045% Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-123 Vehicle Lotion
Description: Vehicle Lotion
Study: NCT00859742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA, integrated PET/CT
Description: EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
Study: NCT03511456

Intervention type: PROCEDURE
Intervention: PELD operation
Description: Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed.
Study: NCT03596450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
Study: NCT03271359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC
Description: Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
Study: NCT02136056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program (SMP)
Description: A self-management course
Study: NCT02160444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus Parent as CBT Coach Training
Description: Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
Study: NCT00772109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal
Study: NCT00985088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: one or two intramuscular injections
Study: NCT00772109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular